Диссертация (1154767), страница 16
Текст из файла (страница 16)
A Prospective Study ofLipoprotein(a) and the Risk of Myocardial Infarction. JAMA J Am Med Assoc.1993;270(18):2195.123. Roffi M, Valgimigli M, Bax JJ, et al. 2015 ESC Guidelines for themanagement of acute coronary syndromes in patients presenting without persistentST-segment elevation. Eur Heart J. 2015;(32):2999-3054.124. Sano M, Bell KL, Glasko D, et al. A randomized, double-blind, placebocontrolled trial of simvastatin to treat Alzheimer disease. Neurology 2011; 77:556–63.125.
Santos RD, Waters DD, Tarasenko L, et al. A comparison of non-HDLand LDL cholesterol goal attainment in a large, multinational patient population.Atherosclerosis. 2012; 224(1): 150-153.105126. Schwartz G, Olsson AG, Ezekowitz MD. et al. Effects of atorvastatin onearly recurrent ischemic study: randomized controlled trial events in acutecoronary syndromes: The MIRACL.
JAMA 2001;285(13):1711-8.127. Scirica BM, Morrow DA, Cannon CP, Ray KK, Sabatine MS, Jarolim P,Shui A, McCabe CH, Braunwald E. Intensive statin therapy and the risk ofhospitalization for heart failure after an acute coronary syndrome in the PROVEIT-TIMI 22 study. J Am Coll Cardiol 2006;47:2326–2331.128. SEARCH Collaborative Group, Link E, Parish S, et al. SLCO1B1 Variantsand Statin-Induced Myopathy — A Genomewide Study.
N Engl J Med.2008;359(8):789-799.129. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, CollinsR, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E,Ostergren J. Prevention of coronary and stroke events with atorvastatin inhypertensive patients who have average or lower-than-average cholesterolconcentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - LipidLowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet2003;361: 1149–1158.130. Shanker J, Perumal G, Rao VS, et al. Genetic studies on the APOA1-C3-A5gene cluster in Asian Indians with premature coronary artery disease.
LipidsHealth Dis. 2008;7:33.131. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM,Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, MeindersAE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, WestendorpRG. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): arandomised controlled trial. Lancet 2002;360:1623–1630.132. Simon JA, Lin F, Hulley SB, Blanche PJ, Waters D, Shiboski S, Rotter JI,Nickerson DA, Yang H, Saad M, Krauss RM. Phenotypic predictors of response tosimvastatin therapy among African-Americans and Caucasians: the cholesterol andpharmacogenetics (CAP) Study.
Am J Cardiol. 2006;97:843–850.106133. Song Y, Zhu L, Richa M, Li P, Yang Y, Li S. Associations of the APOC3rs5128 polymorphism with plasma APOC3 and lipid levels: a meta-analysis.Lipids Health Dis. 2015;14:32.134. Sorrentino S, Landmesser U. Nonlipid-lowering effects of statins. Curr TreatOptions Cardiovasc Med. 2005;7(6):459-466.135. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management ofacute myocardial infarction in patients presenting with ST-segment elevation.
EurHeart J. 2012;33(20):2569-2619.136. Sun Y, Zhou R, Chen D. APOA5 -1131T>C and APOC3 -455T>Cpolymorphisms are associated with an increased risk of coronary heart disease.funpecrp.com.br Genet Mol Res Mol Res. — 2015. —14(144). — C.18218-18228.137. Sundaram M, Zhong S, Bou Khalil M, et al. Expression of apolipoprotein CIII in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-richconditions. J Lipid Res. —2010.
—51(1). — C.150-161.138. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels(SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemicattack. N Engl J Med. — 2006. — 355. — C.549–59.139. Thompson JF, Man M, Johnson KJ, et al. An association study of 43 SNPsin 16 candidate genes with atorvastatin response. Pharmacogenomics. — 2005. —5(6).
— C.352-8.140. Vupputuri S, Joski PJ, Kilpatrick R, et al. LDL cholesterol response andstatin adherence among high-risk patients initiating treatment. Am J Manag Care.— 2016. —22(3). — C.106-115.141. Wang, C.S. Modulation of lipoprotein lipase activity by apolipoproteins.Effect of apolipoprotein C-III / Wang C.S., McConathy W.J., Kloer H.U.,Alaupovic P. // J Clin Invest. — 1985. —75(2). — C.384-390.142. Waters, D.D. Lipid Treatment Assessment Project 2: a multinational surveyto evaluate the proportion of patients achieving low-density lipoprotein cholesterolgoals / Waters D.D., Brotons C., Chiang C.W., et al.
// Circulation. — 2009. —120. — C.28-34.107143. Wiviott, S.D. PROVE IT-TIMI 22 Investigators. Can low-densitylipoprotein be too low? The safety and efficacy of achieving very low low-densitylipoprotein with intensive statin therapy, a PROVE IT-TIMI 22 substudy / WiviottS.D., Cannon C.P., Morrow D.A., Ray K.K., Pfeffer M.A., Braunwald E. // J AmColl Cardiol.
— 2005. — 46. — C.1411–1416.144. Xu, C. Effects of APOA5 −1131T>C (rs662799) on Fasting Plasma Lipidsand Risk of Metabolic Syndrome: Evidence from a Case-Control Study in Chinaand a Meta-Analysis / Xu C., Bai R., Zhang D., et al // Crawford DC, ed. PLoSOne. — 2013. — 8(2). — e56216.145. Xu, M. Apolipoprotein E Gene Variants and Risk of Coronary HeartDisease: A Meta-Analysis / Xu M., Zhao J., Zhang Y. et al. // Biomed Res Int. —2016.
— ID 3912175.146. Yousuf, F.A. Review: Apolipoprotein E (Apo E) gene polymorphism andcoronary heart disease in Asian populations / Yousuf F.A., Iqbal M.P. // J PharmSci. — 2015. —28(4). — C.1439-1444.147. Yu, B.L. A comparison of non-HDL and LDL cholesterol goal attainment inthe CHILLAS trial / Yu B.L., Zhao S.P., Peng D.Q., et al. // Int J Cardiol. —2013.— 168(4). — C.4340-4342.148. Yu, J. Lack of association between apolipoprotein C3 gene polymorphismsand risk of coronary heart disease in a Han population in East China / Yu J., HuangJ., Liang Y., et al.
// Lipids Health Dis. — 2011. —10(1). —C.200.149. Zhang, J. Review APOA5 -1131T/C polymorphism and coronary arterydisease susceptibility in Chinese population: an updated meta-analysis / Zhang J.,Wan D.G., Song H.L., Zhang W.G. // Genet Mol Res. — 2015. — 14(4). —C.12330-12339.150. Zhao, S. Prevalence of dyslipidaemia in patients treated with lipid-loweringagents in China: results of the Dyslipidemia International Study (DYSIS) / ZhaoS., Wang Y., Mu Y., et al. // Atherosclerosis. —2014. — 235(2). — 463e9.151.
Zheng,C.ApolipoproteinC-IIIandtheMetabolicBasisforHypertriglyceridemia and the Dense Low-Density Lipoprotein Phenotype / Zheng108C., Khoo C., Furtado J., Sacks F.M. // Circulation. — 2010. —121(15). —C. 17221734.152. Zhou, Q. Pleiotropic effects of statins. - Basic research and clinicalperspectives / Zhou Q., Liao J.K. // Circulation — 2010. — 74. — C. 818–26.153.
Zhu, H. The association of apolipoprotein E (APOE) gene polymorphismswith atherosclerosis susceptibility: a meta-analysis / Zhu H, Xue H, Wang H, MaY, Liu J, Chen Y. // Minerva Cardioangiol. 2016. —64(1). — C.47-54.154. Zintzaras, E. APOE gene polymorphisms and response to statin therapy /Zintzaras E, Kitsios GD, Triposkiadis F, Lau J, Raman G. // Pharmacogenomics J.— 2009. — 9(4). — C.248-257..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
